During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI. The study was conducted to determine the frequency and outcomes of new suspicious lesions on breast MRI arising during neoadjuvant chemotherapy.
Determine the frequency
A retrospective database review found a total of 419 breast MRI examinations performed in 297 women to evaluate response to neoadjuvant chemotherapy. After exclusions for reasons including a lack of baseline pretreatment MRI for comparison; the final study cohort consisted of 28 MRI examinations (7%) with new suspicious findings.
All cases included in the study are assess as BI-RADS 4. Twenty-five cases had either tissue diagnosis or adequate imaging follow-up to establish a diagnosis of the new suspicious findings on breast MRI. Of these 25 cases; 44% are prove benign at percutaneous biopsy; 20% at surgical pathology; and 36% are assess benign base on follow-up imaging of 2 years or longer. That is; for all 25 cases the cancer yield for new suspicious lesions was 0%.
Signify a new malignancy
Results suggest that new suspicious finding on breast MRI which occur during neoadjuvant therapy are highly unlikely to signify a new malignancy; although the authors encourage further study to confirm whether biopsy may be safely avoided in these circumstances. “They found that new suspicious lesions on MRI are not rare; occurring 7% of the time,” Donna Eckstein, MD, author of the study said.
“Nearly all of these new lesions arose while the index tumor showed treatment response on MRI; and none of these new lesions were malignant. Larger studies across facilities are need to confirm whether biopsy may be safely averted in these scenarios.”The use of neoadjuvant systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of locally advanced disease.
Therapy as a complement
Imaging provides important information in assessing response to therapy as a complement to conventional tumor measurements via physical examination. The purpose of this article is to discuss the advantages and limitations of current assessment methods; as well as review functional and molecular imaging approaches being investigate as emerging techniques for evaluating neoadjuvant therapy response for patients with primary breast cancer.
The RSNA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Because The RSNA designates this journal-based SA-CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.